businesswire.com · 16 jul

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of Car.

businesswire.com · 16 jul

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx's transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for sur.

zacks.com · 7 jul

CareDx Completes Naveris Acquisition and Expands Oncology Reach

CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.

seekingalpha.com · 7 jul

CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder

CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.

businesswire.com · 1 jul

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.

businesswire.com · 30 jun

CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearan.

fool.com · 21 jun

CareDx's CEO Sells 17K Shares

The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.

zacks.com · 19 jun

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.